Per the federal Department of Health and Human Services, "The Recovery Act (ARRA) contains $1.1 billion for comparative effectiveness research. Comparative effectiveness research (CER) compares treatments and strategies to improve health. This information is essential for clinicians and patients to decide on the best treatment. It also enables our nation to improve the health of communities and the performance of the health system. [With respect to CER], ARRA provides $300 million for the Agency for Healthcare Research and Quality; $400 million for the National Institutes of Health, and; $400 million for the Office of the Secretary of Health and Human Services. These funds are to support research assessing the comparative effectiveness of health care treatments and strategies, through efforts that:

• Conduct, support, or synthesize research that compares the clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to prevent, diagnose, or treat diseases, disorders, and other health conditions.
• Encourage the development and use of clinical registries, clinical data networks, and other forms of electronic health data that can be used to generate or obtain outcomes data.

Read the excerpt from the Recovery Act related to comparative effectiveness research."

This site will serve to update UT-Houston investigators and research staff on CER-related extramural funding opportunities. Please check back frequently or contact Peter Davies, Executive Vice President for Research or Johnna Kincaid, Executive Director, OSP, with questions. For other ARRA information, please click here to go to the UTHSC-H ARRA Web site.

Information and Resources as of October 8, 2009

Key Due Dates for CER-related RFAs

CER Funding Opportunities and Announcements as of September 25, 2009

• Letters of Intent are due September 4, 2009
• Applications are due September 23, 2009
• The goal of the FOA is to generate and advance the scientific knowledge of hip and knee replacement procedures and orthopedic devices.
• Applications may be up to four years in duration not to exceed $3 million per year in total costs to the government; applications with project periods that exceed four years or budgets that exceed $12 milliontotal costs will not be reviewed.
• Applicants may submit more than one application, provided each application is scientifically distinct.

Recovery Act Limited Competition: AHRQ Clinical & Health Outcomes Initiative in Comparative Effectiveness (CHOICE) Grants (R01) *9/25/09*

• Letters of Intent are due November 16, 2009
• Applications are due December 16, 2009
• The goal of the FOA is to generate new knowledge to help inform decision maiking in high priority areas of clinical care. The impact of these studies should have a high likelihood of creating major advancements in clinical care.
• Applications may be up to three years in duration not to exceed $10 million in total costs over the entire project period. A total of 10 awards will be made.
• Applicants may submit more than one application, provided each application is scientifically distinct.

• Letters of Intent are due November 16, 2009
• Applications are due December 16, 2009
• The goal of the FOA is to propose new customizations or adaptations to the content presentation and/or delivery mechanism(s) of one or more CER review products.
• Applications may be up to three years in duration not to exceed $1.5 million in total costs over the entire project period. An anticipated 20-25 awards will be made.
• Applicants may submit more than one application, provided each application is scientifically distinct.

Questions and Comments

Agency Site Links